KR101736033B1 - Lactobacillus sakei with activity of anti-obesity - Google Patents

Abstract

The present invention relates to a lactobacillus sakei WIKIM31 strain and a use thereof and, more specifically, to a lactobacillus sakei WIKIM31 strain having an inhibitory effect on adipocyte differentiation and a body fat reducing effect.

Description

Lactobacillus sakei with activity of anti-obesity < RTI ID = 0.0 >

The present invention relates to Lactobacillus sakeae having anti-obesity activity.

As humanity develops into a rich society, obesity is becoming a serious disease, and the World Health Organization (WHO) specifies obesity as the target of diseases to be treated. In Korea, the frequency of obesity is increasing according to Westernized eating habits, and there is a growing interest in the treatment and prevention of obesity.

  Currently known obesity treatments include Xenical (Roche Pharmaceuticals, Switzerland), Reductil (Evothe, USA) and Exolise (Atopama, France). The above-mentioned obesity treatment agents are classified largely into an appetite suppressant, an energy consumption promoter or a fat absorption inhibitor. Most of the obesity treatment agents are appetite suppressants that suppress the appetite by controlling the neurotransmitters associated with the hypothalamus. However, conventional therapeutic agents cause side effects such as heart diseases, respiratory diseases and nervous system diseases, and the persistence of the effects is low, so it is necessary to develop a therapeutic agent for obesity with improved therapeutic effect. In addition, there is no satisfactory treatment without side effects and development of new obesity treatment is required.

On the other hand, many studies have been conducted to prevent or treat obesity by using fungi (for example, lactic acid bacteria) that have been regarded as safe microorganisms. Lactic acid bacteria have been reported to have effects such as maintenance of intestinal microflora, improvement of intestinal flora, antidiabetic and antiproliferative effect, carcinogenesis inhibition, colorectal cancer suppression, and nonspecific activity of host immune system.

Especially, the lactic acid bacteria isolated from kimchi have been reported to have the effect of enhancing the kingdom, antimicrobial effect, antioxidant effect, anti-cancer effect, anti-obesity effect, hypertension prevention effect and constipation prevention effect as lactic acid bacteria involved in fermentation of kimchi (Non-Patent Document 1 3).

Lactobacillus plantarum KY1032 (10-2012-0034482, KCCM-10430), Lactobacillus curvatus HY7601 (10th-10th -0034482, KCCM-10430) -0996577, KCTC 11456BP), Lactobacillus plantarum DSR920 (10-2013-0046896, KCCM 11210P) or Lactobacillus johnsonii HF1 108 strain (No. 10-2010-0010015 , KCTC 11356BP).

However, no commercially available lactic acid bacteria-related technology with excellent anti-obesity effect appeared. Therefore, screening of novel strains with excellent anti-obesity effect and their various functions need to be clarified.

1. Hivak P, Odrska J, Ferencik M, Ebringer L, Jahnova E, Mikes Z.: One-year application of Probiotic strain Enterococcus facium M-74 increase Serum cholesterol levels. : Bratisl lek Listy 2005; 106 (2); 67-72; 2. Agerholm-Larsen L. Bell ML. Grunwald GK. Astrup A.: The effect of a probiotic milk product on plasma cholesterol: a metaanalysis of short-term intervention studies; Eur J Clin Nutr. 2000; 54 (11) 856-860; 3. Renato Sousa, Jaroslava Helper, Jian Zhang, Strephen J Lewis and Wani O Li; Effect of Lactobacillus acidophilus supernants on body weight and leptin expression in rats; BMC complementary and alternative medicine. 2008; 8 (5) 1-8].

The present invention relates to a strain of Lactobacillus sakei WIKIM31 (WIKIM31, KFCC11654P) and its use, and is intended to provide a lactobacillus skeeti strain having an effect of inhibiting adipocyte differentiation and reducing body fat.

The present invention provides Lactobacillus sakei WIKIM31 and KFCC11654P strains having an activity of inhibiting adipocyte differentiation and reducing body fat.

In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity or obesity-related diseases comprising the above-mentioned strains, a culture thereof, a crushed product thereof or an extract thereof.

The present invention also provides a food composition for preventing or ameliorating an obesity or obesity-related disease comprising the above-mentioned strain, a culture thereof, a crushed product thereof or an extract thereof.

The Lactobacillus sakei WIKIM31 and KFCC11654P strains according to the present invention inhibit the differentiation of 3T3-L1 adipocytes, inhibit fat accumulation, inhibit the expression of genes involved in adipocyte differentiation, inhibit fat accumulation in the body The body fat reduction effect is very excellent.

Therefore, it can be used as a pharmaceutical composition and functional food affecting fat metabolism.

FIG. 1 is a photograph and a graph showing the results of measurement of changes in fat accumulation amount according to the treatment of the strain extract. FIG.
FIG. 2 is a graph showing the results of measurement of changes in gene expression of adipocyte differentiation and transcription-related factors upon treatment with a strain extract.
FIG. 3 is a graph showing a result of measuring a change in body weight according to ingestion of a strain. FIG.
FIG. 4 is a table showing the result of measuring the change in body weight gain with the ingestion of the strain.
FIG. 5 is a graph showing the results of measurement of changes in fat mass and body fat mass according to consumption of a strain.
FIG. 6 is a graph showing the results of measurement of changes in liver function values according to the ingestion of a strain. FIG.
FIG. 7 is a graph showing the results of measurement of hormone changes according to ingestion of a strain. FIG.

The present invention relates to Lactobacillus sakei WIKIM31 and KFCC11654P strains having an adipocyte differentiation inhibiting activity and a body fat reducing effect.

In the present invention, the term "culture product" means a product obtained by culturing a strain in a known liquid medium or solid medium and includes a strain.

The terms " pharmaceutically acceptable "and" pharmaceutically acceptable "in the present invention are intended to mean not significantly irritating the organism and not interfering with the biological activity and properties of the administered active substance.

In the present invention, "prevention" means any action that inhibits the symptoms of, or delays the progression of, a particular disease (e. G., Fatty liver) upon administration of the composition of the present invention.

In the present invention, "treatment" means any action that improves or alleviates the symptoms of a particular disease (e. G., Fatty liver) upon administration of the composition of the present invention.

In the present invention, "improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated, for example.

In the present invention, "administration" means providing the desired composition of the present invention to an individual by any suitable method. The term " individual " means any animal such as a human, a monkey, a dog, a goat, a pig, or a mouse having a disease in which symptoms of a specific disease can be improved by administering the composition of the present invention.

The term "pharmaceutically effective amount " in the present invention means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, and includes an amount of the disease of the individual, severity, activity of the drug, The drug's sensitivity, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including simultaneously used drugs, and other factors well known in the medical arts.

Hereinafter, the present invention will be described in detail.

The Lactobacillus sakei WIKIM31 and KFCC11654P strains (hereinafter, referred to as WIKIM31 strains) according to the present invention have an adipocyte differentiation inhibiting activity and a body fat reducing effect.

The WIKIM31 strain may contain the nucleotide sequence shown in SEQ ID NO: 1 as 16S rDNA.

The strain WIKIM31 according to the present invention can be isolated from kimchi, for example, Chinese cabbage kimchi or mustard kimchi.

The present invention also relates to the various uses of the novel strain WIKIM31 described above.

For example, the present invention provides a composition for preventing, ameliorating or treating obesity or obesity-related diseases comprising the WIKIM31 strain, a culture thereof, a crushed product thereof or an extract thereof as an active ingredient.

The culture is a product obtained by culturing in a WIKIM31 strain culture medium. The culture medium may be selected from known liquid culture media or solid culture media, for example, MRS liquid culture medium and MRS agar culture medium.

The WIKIM31 strain, the culture thereof, the lysate thereof or the extract thereof according to the present invention has various functions such as anti-obesity activity, adipocyte differentiation inhibitory activity and body fat decreasing effect, so that it can prevent, ameliorate or treat obesity or obesity-related diseases It can be used as an active ingredient. The above-mentioned obesity-related diseases are not limited to those caused by obesity or those having a high correlation with obesity, for example, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, atherosclerosis and lipid-related metabolic syndrome Can be selected. In addition, the lipid-related metabolic syndrome may be a disease in which various metabolic diseases such as diabetes and obesity occur simultaneously in one person.

In addition, the composition according to the present invention may be used in combination with Lactobacillus brevis , Lactobacillus plantarum , Lactobacillus sake , or the like to improve the preventive, ameliorative or therapeutic effect of obesity- , Leuconostoxesteroid ( Leuconostoc mesenteroides and Weissella < RTI ID = 0.0 > koreensis ). < / RTI >

The composition for preventing, ameliorating or treating obesity or obesity-related diseases of the present invention may be formulated into pharmaceutical compositions, food additives, food compositions (in particular, functional food compositions), feed additives or the like, The content of the fermented product fermented with the WIKIM31 strain as an active ingredient in the composition may be adjusted in various ranges depending on the specific form of the composition, the purpose of use, and the manner of use.

In the pharmaceutical composition for preventing or treating obesity or obesity-related diseases according to the present invention, the content of the active ingredient WIKIM31 strain, the culture thereof, the lysate thereof or the extract thereof is not particularly limited and may be, for example, 0.01 To 99% by weight, preferably 0.5 to 50% by weight, more preferably 1 to 30% by weight.

The pharmaceutical composition according to the present invention may further comprise, in addition to the active ingredient, an additive such as a pharmaceutically acceptable carrier, excipient or diluent. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition of the present invention can be formulated into a formulation for oral administration or parenteral administration by a conventional method, and can be formulated into a pharmaceutical composition such as a filler, an extender, a binder, a wetting agent, a disintegrant, Diluents or excipients. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA in a suitable manner in the art. The pharmaceutical composition of the present invention may be administered orally or parenterally to a mammal including a human according to a desired method. Examples of the parenteral administration method include external dermal application, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravenous injection, Intravenous injection or intra-thoracic injection. The dosage of the pharmaceutical composition of the present invention is not limited as long as it is a pharmacologically effective amount and is not limited as long as it depends on the body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, Varies. The typical daily dose of the pharmaceutical composition of the present invention is not particularly limited, but is preferably 0.1 to 3000 mg / kg, more preferably 1 to 2000 mg / kg, based on the active ingredient, once a day Or may be administered in divided doses.

In the food composition for preventing or ameliorating obesity or obesity-related diseases according to the present invention, the content of the active ingredient WIKIM31 strain, the culture thereof, the lysate thereof or the extract thereof is 0.01 to 50% by weight, Is 0.1 to 25% by weight, more preferably 0.5 to 10% by weight, but is not limited thereto. The food composition of the present invention may be in the form of a pill, a powder, a granule, an infusion, a tablet, a capsule, or a liquid preparation. Examples of the food include meat, sausage, bread, chocolate, candy, snack, Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, functional water, drinks, alcoholic beverages and vitamin complexes. The food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient in addition to the active ingredient. In addition, the food composition of the present invention can be used as a food composition containing various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Natural flavors such as tau Martin and stevia extract, and synthetic flavors such as saccharin and aspartame may be used as the flavor.

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Example

1. Isolation of strain, production of culture extract

The strains were harvested from a domestic home in Gangwon - do, and Kimchi lactic acid bacteria were isolated.

The collected kimchi samples were crushed, filtered, diluted at a magnification of 10 ⁶ to 10 ⁹ , plated on Lactobacilli MRS (Difco) agar medium, and cultured for 24 hours or more. After colony formation, cultured lactic acid bacteria were selected and cultured. The cells were screened for lipid accumulation during adipocyte differentiation and finally identified by 16S RNA sequencing. Among them, one kind of lactic acid bacteria having excellent effect was named LIKE Lactobacillus sakei WIKIM31 by giving the unique number of WIKIM31 from the Kimchi Institute Microbiology Gene Bank of the world.

The strain extracts were cultured in MRS medium at 30 ° C. for 24 hours. The cells were centrifuged at 12,000 rpm for 10 minutes and rinsed with PBS (phosphate buffered saline) to remove the remaining medium. The cells were washed with 1 × 10 ⁹ after resuspension in a concentration of CFU / ml using a ^{FastPrep-24 ⓡ sample preparation system (} MP Biomedicals, CA, USA) was lysis the cells. This was centrifuged at 12,000 rpm for 10 minutes and then used in the supernatant.

Statistical analysis was performed using the SPSS 18.0 program. Statistical analysis was performed using the Duncan's multiple range test of the one-way ANOVA. The significance was tested at 0.05 level.

2. Measurement of lipid accumulation during adipocyte differentiation

To determine the effect of Lactobacillus sakei WIKIM31 extract on fat accumulation in lipid differentiation, Oil Red O staining was performed according to the method of Negrel and Dani.

After 2 days of 100% confluent stage, the cells were treated with 1.0 × ^{10 8} CFU / ml of strain extract at the time of replacement with adipogenic cocktail, insulin and FBS cultures. After 9 days of differentiation, the culture broth was removed and washed with PBS And fixed with 10% formaldehyde for 10 minutes. 10% formaldehyde was removed and the cells were fixed for more than 1 hour by adding saturated formaldehyde again. After that, 60% isopropanol was added to the flask. The flask was washed with distilled water, stained with oil red O staining solution for 30 minutes, and washed with distilled water. The intracellular fat accumulation of dyed lipids was observed using a microscope and the effect of the extract of the strains on lipid accumulation was observed visually. To confirm the accumulation of fat, isopropanol was added to the dried oil to elute the oil red O dye, and the absorbance was measured at 500 nm using a multi-plate reader.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph and a graph showing the result of measurement of fat accumulation by treatment with Lactobacillus sakei WIKIM31 extract of Lactobacillus sakei WIKIM31. In FIG. 1, the normal group refers to undifferentiated adipocytes that do not induce differentiation into precursor adipocytes, and the control refers to completely differentiated adipocytes.

The differentiated adipocyte layer was stained with Oil red O and photographed. (A) is a photographic image, and (b) is a photographic image obtained by using a microscope and photographed (100 X magnification). In addition, (C) is a graph showing a quantified lipid content.

When treated with WIKIM31 extract, lipid content was significantly reduced at 10% concentration (see FIG. 1) when compared to the differentiated fat cells without the strain extract (control group). Therefore, the extract of Lactobacillus sakei WIKIM31 according to the present invention is expected to have an anti-obesity effect and a body fat reduction effect.

2 is a graph showing the results of measuring the adipocyte differentiation and transcription-related factors of 3T3-L1 pre-adipocytes according to the strain extract treatment.

(PPAR-γ), C / EBP-α (CCAAT / enhancer binding protein-α), SREBP-1c (sirtol regulatory element-binding protein-1c) and aP2α activator protein 2 alpha), FAS (Fatty acid synthase) and GLUT4 (glucose transporter type 4).

As a method of inducing adipocyte differentiation, the strain was treated with a concentration of 1.0 × ^{10 8} CFU / ml, and then differentiated for 9 days. In order to confirm the expression level of the genes involved in adipocyte differentiation, PCR (Real time quantitative) was performed . Total RNA of adipocytes was isolated using Trizol reagent (Invitrogen, Carlsbad, Calif.). 1 ng of each separated RNA was synthesized using TOPscript ^TM cDNA synthesis kit (Enzynomics, Daejeon, Korea) and S1000 Thermal Cycler (Bio-Rad, USA). The synthesized cDNA was amplified using BioRad CFX-96 real time system (BioRad) with primers, nuclease-free water, TOPreal ^™ qPCR 2x PreMIX (SYBR Green) and primers. As a control gene, β-actin primer was used.

(A) PPARγ (B) C / EBPα, (C) SREBP-1c, (D) aP2α, (E) FAS and (F) It is confirmed that the expression of GLUT4 gene is decreased.

3. Measurement of weight loss efficacy

Four-week-old male C57BL / 6J mice were adapted to chow diet (CD; Purina, Korea) for 1 week under a temperature of 20 ± 2 ° C, a humidity of 50 ± 5% and a light- The animals were divided into two groups: normal (n = 6), corn oil (5% wt.wt), high fat diet (n = 6) (D12451, Research Diets, New Brunswick, NJ) were fed for 10 weeks, and 45% of total calories were fed a fat diet. After high fat diet for 1 week, high fat diet group was divided into two groups (HFD, HFD + WIKIM31) by 6 groups. The HFD group was fed with high fat diets and phosphate buffered saline (PBS) (HFD + WIKIM31) was fed a high fat diet, and Lactobacillus sakei WIKIM31 was suspended in phosphate buffered saline (PBS) for 10 weeks. In addition, a normal diet was fed with a normal diet and the same amount of phosphate buffered saline (PBS) as in the HFD group was orally administered for 5 weeks. At this time, WIKIM31 was orally administered at a concentration of 1 × 10 ⁹ CFU / 200 μl / day on a daily basis.

After 10 weeks, the mice were observed for weight change due to the strain ingestion.

3 is a graph showing changes in body weight during a 10-week period in a mouse, and FIG. 4 is a chart showing a weight increase during a 10-week period.

As shown in FIG. 3 and FIG. 4, when WIKIM31 was administered (HFD + WIKIM31), the body weight of the high fat diet was significantly decreased and the body weight increase was also decreased compared with the intake high fat diet (HFD) .

4. Measurement of fat tissue weight change

Total body fat was measured using an EchoMRI ^™ -500 Body Composition Analyzer for body composition analysis of live mice that received WIKIM31, inducing obesity for 10 weeks.

The epididymal fat and the abdominal fat of the experimental animals were removed at the end of the experiment, washed with physiological saline, and the water was removed from the filter paper and then weighed.

FIG. 5 is a graph showing the results of measurement of fat weight and body fat mass in the present invention.

As shown in FIG. 5, when the WIKIM31 was administered (HFD + WIKIM31), the high fat diet showed a decrease in fat weight such as epididymal fat and abdominal fat compared with the intake mice (HFD) And thus it can be confirmed that the amount of body fat is reduced.

5. Measurement of GOT and GPT in blood

Using the method of 3., the mice receiving WIKIM31 inducing obesity for 10 weeks were fasted for 24 hours before the end of the experiment, and then blood was collected from the abdominal vena cava and serum was separated and used for the experiment. Glutamic oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) concentrations in the blood were measured using an automated biochemical analyzer (FUJI DRI-CHEM 7000i, Fujifilm, Tokyo, Japan).

FIG. 6 is a graph showing changes in the concentrations of GOT and GPT according to the strain ingestion.

As shown in FIG. 6, when WIKIM31 was administered (HFD + WIKIM31), it was confirmed that the GOT and GPT concentrations were significantly decreased compared to the high-fat diet fed mice (HFD). In particular, since the concentration of GOT and GPT in HFD + WIKIM31 is lower than that in the normal diet group, it can be confirmed that the strain according to the present invention, namely WIKIM31, is highly effective in improving liver function.

6. Measurement of blood hormone changes

Using the method of 3., the serum of the mice to which WIKIM31 was administered with induction of obesity for 10 weeks was used to measure changes in blood hormones. Serum hormones were measured on a Bio-plex MAGPIX ^™ Multiplex Reader using a Bio-plex diabetes assay plex (Bio-rad).

Leptin, plasminogen activator inhibitor-1 (PAI-1), and resistin increase in blood levels as the body fat tissue increases.

FIG. 7 is a graph showing the results of measuring the hormone changes according to the strain ingestion.

As shown in FIG. 7, when the WIKIM31 was administered (HFD + WIKIM31), the blood levels of Leptin, PAI-1 and Resistin, which are hormones in the blood, were significantly decreased compared with the fed mice (HFD) .

Name of depository: Korea Microorganism Conservation Center (Domestic)

Accession number: KFCC11654P

Deposit date: March 3, 2016

<110> Korea Food Research Institute <120> Lactobacillus sakei with activity of anti-obesity <130> P15R10C1843 <160> 1 <170> Kopatentin 2.0 <210> 1 <211> 1518 <212> RNA <213> Lactobacillus sakei WIKIM31 <400> 1 ctcaggttga acgctgggcg cgtgcctaat aacagcaagt cgaacgcact ctcgtttaga 60 ttgaaggagc ttgcttctga ttgattaaca tttgagtgag tggcggacgg gtgagtaaca 120 cgtgggtaac ctgccctaaa gtgggggata acatttggaa acagatgcta ataccgcata 180 aaacctaaca ccgcatggtg tagggttgaa agatggtttc ggctatcact ttaggatgga 240 cccgcggtgc attagttagt tggtgaggta aaggctcacc aagaccgtga tgcatagccg 300 acctgagagg gtaatcggcc acactgggac tgagacacgg cccagactcc tacgggaggc 360 agcagtaggg aatcttccac aatggacgaa agtctgatgg agcaacgccg cgtgagtgaa 420 gaaggttttc ggatcgtaaa actctgttgt tggagaagaa tgtatctgat agtaactgat 480 caggtagtga cggtatccaa ccagaaagcc acggctaact acgtgccagc agccgcggta 540 atacgtaggt ggcaagcgtt gtccggattt attgggcgta aagcgagcgc aggcggtttc 600 ttaagtctga tgtgaaagcc ttcggctcaa ccgaagaagt gcatcggaaa ctgggaaact 660 tgagtgcaga agaggacagt ggaactccat gtgtagcggt gaaatgcgta gatatatgga 720 agaacaccag tggcgaaggc ggctgtctgg tctgtaactg acgctgaggc tcgaaagcat 780 gggtagcaaa caggattaga taccctggta gtccatgccg taaacgatga gtgctaggtg 840 ttggagggtt tccgcccttc agtgccgcag ctaacgcatt aagcactccg cctggggagt 900 acgaccgcaa ggttgaaact caaaggaatt gacgggggcc cgcacaagcg gtggagcatg 960 tggtttaatt cgaagcaacg cgaagaacct taccaggtct tgacatcctt tgaccactct 1020 agagatagag ctttcccttc ggggacaaag tgacaggtgg tgcatggttg tcgtcagctc 1080 gtgtcgtgag atgttgggtt aagtcccgca acgagcgcaa cccttattac tagttgccag 1140 catttagttg ggcactctag tgagactgcc ggtgacaaac cggaggaagg tggggacgac 1200 gtcaaatcat catgcccctt atgacctggg ctacacacgt gctacaatgg atggtacaac 1260 gagttgcgag accgcgaggt ttagctaatc tcttaaaacc attctcagtt cggattgtag 1320 gctgcaactc gcctacatga agccggaatc gctagtaatc gcggatcagc atgccgcggt 1380 gaatacgttc ccgggccttg tacacaccgc ccgtcacacc atgagagttt gtaacaccca 1440 aagccggtga ggtaaccctt cggggagcca gccgtctaag gtgggacaga tgattagggt 1500 gaagtcgtac aggggaaa 1518

Claims (6)

Lactobacillus sakei WIKIM31 (KFCC11654P) strain having an activity of inhibiting adipocyte differentiation and having a body fat reducing effect.
The method according to claim 1,
Lactobacillus sakei WIKIM31, KFCC11654P) strain isolated from kimchi.
A pharmaceutical composition for preventing or treating obesity, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis or lipid-related metabolic syndrome comprising the strain according to claim 1, a culture thereof, a crushed product thereof or an extract thereof.
delete The method of claim 3,
Lactobacillus brevis , Lactobacillus plantarum , Lactobacillus sake , Leuconostocensenteroids ( Leuconostoc mesenteroides , and Weissella koreensis . &lt; RTI ID = 0.0 &gt; 21. &lt; / RTI &gt;
A food composition for preventing or ameliorating an obesity, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis or lipid-related metabolic syndrome comprising the strain according to claim 1, a culture thereof, a crushed product thereof or an extract thereof.

Images